CEOI MEMBER SINCE 2020

Adam Schechter is chairman, president, and CEO of Labcorp. He was named CEO in November 2019 and chairman in May 2020 after serving on the board since 2013. Under Mr. Schechter’s leadership, Labcorp leverages its combined expertise in drug development and diagnostics to advance health care across major clinical and therapeutic areas, including autoimmune, infectious disease, neurology, oncology, and women’s health. With these capabilities, the company is helping to bring innovative, life-changing testing, treatments, and vaccines to market and has created a model for addressing emerging health crises with its response to the COVID-19 pandemic and mpox virus. Mr. Schechter joined Labcorp after a long and distinguished career at Merck, where he served as executive vice president, president of global human health, and as a member of the executive committee. He focused on launching new medicines and vaccines such as Keytruda, Januvia, and Gardasil; led a large global organization across the spectrum of commercial operations; transformed Merck’s commercial model; and led the integration of Merck and Schering-Plough. Mr. Schechter is the vice chair of the board of directors for the American Clinical Laboratory Association, a board member for Water.org, chair of the corporate advisory council of the National Alliance for Hispanic Health, and executive advisor to the Healthy Americas Foundation. He also serves as an independent director on the board of DaVita, Inc. Mr. Schechter holds a bachelor’s degree in biology from La Salle University and was awarded an honorary doctor of humane letters degree from the university in 2021.